久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

BeiGene's cancer therapy gets green light

By Liu Zhihua | chinadaily.com.cn | Updated: 2020-04-12 18:32
Share
Share - WeChat
Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn]

China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.

The NMPA approval is based on the clinical results from a single-arm, multi-center pivotal Phase 2 trial of tislelizumab in patients in China and South Korea.

Among patients who were evaluable for response, with a minimum follow-up of 12 months and a median follow-up of 14 months, the objective response rate (ORR) as assessed by the independent review committee was 24.8 percent, and the complete response (CR) rate was 9.9 percent.

The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.

According to Ye Dingwei, vice-president of Fudan University Shanghai Cancer Center, patients with advanced UC have limited treatment options, and it is great that tislelizumab, a new immuno-oncology treatment, becomes available to them.

Supported by encouraging efficacy and safety results from the trial, tislelizumab is believed to bring significant benefits to the patients, he said.

The company also has a broad development program for tislelizumab that encompasses 15 potentially registration-enabling trials globally and in China, in indications including lung, liver, esophageal, gastric, nasopharyngeal, and MSI-H or dMMR cancers, in addition to classical Hodgkin's lymphoma and UC.

"This is our third new drug application approval in the past five months for our internally developed products, a tremendous accomplishment for a young biotechnology company like BeiGene and validation of the team's hard work," said John V. Oyler, the company's chairman, co-founder, and CEO.

"Our strategy for tislelizumab has always been to pursue a broad label and serve patients who are battling different types of cancer. With tislelizumab's first solid tumor approval, we are even more excited about the outlook for this immunotherapy than ever."

However, like other immune checkpoint inhibitors, tislelizumab could cause immune-related adverse reactions that mainly include pneumonitis, diarrhea and colitis, hepatitis, and endocrinopathies (hypothyroidism, hyperthyroidism and thyroiditis, adrenocortical insufficiency, hyperglycemia and type 1 diabetes mellitus), and skin adverse reactions. Occasionally, nephritis, pancreatitis, myocarditis, myositis, and other immune-related adverse reactions were also reported, the company said in a release.

Most common adverse reactions included rash, fatigue, and increased alanine aminotransferase.

The recommended dose of tislelizumab is 200 mg administered as an intravenous infusion every three weeks until disease progression or intolerable toxicity.

Tislelizumab is not approved for use outside China.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 99视频在线免费 | 亚洲国产一级毛片 | 成人欧美午夜视频毛片 | 亚洲欧洲日产国码二区在线 | 露脸 在线 国产 眼镜 | 一个人看的免费高清视频日本 | 手机黄色网址 | 成人69| 欧美成人片在线 | 一级黄视频 | 青青草色久综合网 | 欧美成人免费大片888 | 欧美国产一区二区 | 一区二区三区精品国产欧美 | 亚洲精品欧美日韩 | 国产三a级日本三级日产三级 | 欧美成人久久久免费播放 | 亚洲精品自产拍在线观看 | 日本不卡免费高清视频 | 成年午夜| 欧美粗又大gay69视频 | 男女午夜爱爱久久无遮挡 | 国产a免费观看 | 国产夫妇精品自在线 | 免费黄色美女视频 | 在线观看日本免费视频大片一区 | 国产一区中文字幕在线观看 | 男人天堂亚洲 | 免费v片在线看 | 欧美一级视频在线高清观看 | 日本一级特黄aa毛片免费观看 | 日韩不卡一区二区三区 | 亚洲自偷自偷图片在线高清 | 国产成人精品日本亚洲网站 | 综合自拍| 日韩欧美国产成人 | 国产视频软件在线 | 香蕉视频国产精品 | 国产精品视频第一区二区三区 | 欧美特黄一级高清免费的香蕉 | 神马午夜在线 |